The Nordic Venture Network, a group of leading Nordic venture capital firms including Sunstone, is launching a new performance index aimed at credibly showing the actual returns from the industry.
More details on the study and the results in the presentation and press released attached.
Sunstone Life Science Ventures Fund I porteføljeselskab Nuevolution AB, som arbejder på at udvikle fremtidens banebrydende medicin til behandling af kræft og inflammatoriske sygdomme, planlægger en notering af sine aktier samt optagelse til handel på Nasdaq First North Premier, Stockholm.
Sunstone Life Science Ventures Fund I portfolio company Nuevolution A/S appoints Professor Mark C. Genovese, MD as Scientific Advisor to support the company’s pre-clinical and clinical efforts in inflammatory diseases.
Sunstone Life Science Ventures Fund I portfolio company Nuevolution A/S today announced that it has entered into collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, using Nuevolution’s proprietary Chemetics® drug discovery platform. The collaboration was facilitated by Johnson & Johnson Innovation, in partnership with Janssen Discovery Sciences.
Sunstone Life Science portfolio company Alligator Bioscience AB, a privately held Swedish biotech company developing immuno-oncology antibodies for directed immunotherapy of cancer, today announced that it has entered into a definitive agreement with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Under the agreement, Janssen, will be granted an exclusive, worldwide license to Alligator’s clinical candidate ADC-1013. The collaboration was facilitated by the Johnson & Johnson Innovation Center in London. Currently in Phase I clinical trials, ADC-1013 is an agonistic fully human monoclonal antibody targeting CD40, an immuno-stimulatory receptor found on antigen-presenting cells such as dendritic cells. Stimulation of CD40 on dendritic cells initiates a process leading to a dramatic increase in T effector cells attacking the tumor. In addition, a tumor-specific memory is established leading to long term immunity to the cancer.